Human Genome

Analysis of gene knockouts yields more than 20 drug discovery programs

Published in Gene Therapy Weekly, October 23rd, 2003

Lexicon Genetics, Inc., (LEXG) announced that it has completed its initial analysis of the physiological functions of more than 1250 genes.

This milestone represents the completion of one quarter of Lexicon's Genome5000 program for the discovery of new drug targets from the human genome. The company expects to continue the analysis of the remaining genes at a rate of approximately 1000 genes per year.

"We have now harvested more than 20 drug discovery programs from the human genome in major areas of medical need, including Alzheimer's disease, diabetes, obesity, cancer, inflammation, and heart disease," said Arthur T. Sands, MD, PhD, Lexicon's...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-10-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry